Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2007 2
2010 1
2011 3
2012 2
2013 3
2014 2
2015 6
2016 14
2017 18
2018 25
2019 14
2020 26
2021 2
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33376102

107 results
Results by year
Filters applied: . Clear all
Page 1
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O. Torres VE, et al. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):48-58. doi: 10.2215/CJN.10250620. Epub 2020 Dec 29. Clin J Am Soc Nephrol. 2020. PMID: 33376102
A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.
Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D. Shoaf SE, et al. Clin J Am Soc Nephrol. 2020 May 7;15(5):643-650. doi: 10.2215/CJN.08170719. Epub 2020 Apr 2. Clin J Am Soc Nephrol. 2020. PMID: 32241780
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA. Watkins PB, et al. Drug Saf. 2015 Nov;38(11):1103-13. doi: 10.1007/s40264-015-0327-3. Drug Saf. 2015. PMID: 26188764 Free PMC article.
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H, McEwan P, Hamilton K, O'Reilly K. Bennett H, et al. BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5. BMC Nephrol. 2019. PMID: 31014270 Free PMC article. Clinical Trial.
Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial.
Muto S, Okada T, Yasuda M, Tsubouchi H, Nakajima K, Horie S. Muto S, et al. Drug Healthc Patient Saf. 2017 Oct 25;9:93-104. doi: 10.2147/DHPS.S142825. eCollection 2017. Drug Healthc Patient Saf. 2017. PMID: 29123425 Free PMC article.
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE. Edwards ME, et al. Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19. Clin J Am Soc Nephrol. 2018. PMID: 30026287 Free PMC article. Clinical Trial.
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.
Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD. Devuyst O, et al. Kidney Int Rep. 2017 Jul 21;2(6):1132-1140. doi: 10.1016/j.ekir.2017.07.004. eCollection 2017 Nov. Kidney Int Rep. 2017. PMID: 29270521 Free PMC article.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. N Engl J Med. 2017. PMID: 29105594 Free article. Clinical Trial.
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Torres VE, et al. Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17. Am J Kidney Dis. 2011. PMID: 21333426 Clinical Trial.
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. Am J Nephrol. 2017;45(3):257-266. doi: 10.1159/000456087. Epub 2017 Feb 7. Am J Nephrol. 2017. PMID: 28166521 Free PMC article. Clinical Trial.
107 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback